Qsymia

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
051020122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but… (More)
  • table 1
  • table 2
  • table 3
  • table 5
  • table 4
Is this relevant?
2015
2015
Almost 70% of adults in the United States are overweight, and of these, one-third are clinically obese. Obesity is associated… (More)
  • table 1
Is this relevant?
Review
2014
Review
2014
Obesity is a risk factor for a wide range of conditions, including cardiovascular disease. Although lifestyle modifications… (More)
Is this relevant?
Review
2014
Review
2014
As obesity rates continue to rise in the United States, both physicians and patients have demanded more safe and effective drug… (More)
Is this relevant?
Review
2014
Review
2014
OBJECTIVE To estimate the incremental cost-effectiveness of clinically proven nonsurgical commercial weight loss strategies for… (More)
Is this relevant?
2013
2013
Phentermine/topiramate extended-release capsules (Qsymia) for weight loss. 
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2013
2013
Obesity remains a prominent public health concern in the United States as well as many other countries, with 33% of adults… (More)
  • table 1
Is this relevant?
Review
2013
Review
2013
BACKGROUND Obesity is a serious and costly disease that is growing in epidemic proportions. Obesity-related hospitalizations have… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
n engl j med 367;17 nejm.org october 25, 2012 1577 are manifold, potentially involving all major organ systems and contributing… (More)
Is this relevant?